Next Generation Sequencing (NGS) analysis of 121 Brazilian patients with advanced NSCLC in a retrospective study demonstrated that 20.86% (24/115 valid samples) had KRAS mutations and 1 (0.87%) had KRAS amplification. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.